Moving On From A Botched Novartis AG Deal, Proteon Therapeutics, Inc. Turns To Plan B: IPO

Published: Sep 17, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

It wasn’t too long ago that Proteon Therapeutics looked to be a piece of Novartis’ portfolio. That deal flamed out, however, leading the Waltham, MA-based biotech to retrench, find some new investors, and—as the company as just disclosed today—chart a course for Wall Street.

Proteon has unveiled plans to go public, aiming primarily to finance the ongoing clinical development of PRT-201, a drug that’s supposed to boost the success rates of a surgical procedure often used to prepare kidney failure patients for dialysis. The SEC filing isn’t necessarily a surprise—Proteon raised a big $45 million round four months ago and added a few “crossover” investors to its syndicate like Abingworth and Deerfield Management. All told, Proteon has raised more than $120 million in venture cash since its inception in 2006.

Help employers find you! Check out all the jobs and post your resume.

Back to news